Phase 3 Clinical Trials With Primary Completion Dates in November 2016

This is a list of Phase 3 trials with primary completion dates in November 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AERI Aerie Pharmaceuticals, Inc. 2016-11-01 Phase 3 NCT02558374 Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
CBPO China Biologic Products, Inc. 2016-11-01 Phase 3 NCT02623556 Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
CLDX Celldex Therapeutics, Inc. 2016-11-01 Phase 3 NCT01480479 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
FGEN FibroGen, Inc 2016-11-01 Phase 3 NCT02652806 FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
HZNP Horizon Pharma plc 2016-11-01 Phase 3 NCT02415127 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
MMSI Merit Medical Systems, Inc. 2016-11-01 Phase 3 NCT02159898 EndoMAXX EVT Compared to EndoMAXX
NWBO Northwest Biotherapeutics, Inc. 2016-11-01 Phase 3 NCT00045968 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
ONTX Onconova Therapeutics, Inc. 2016-11-01 Phase 3 NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
OTIC Otonomy, Inc. 2016-11-01 Phase 3 NCT02801370 Phase 3 Study of OTO-201 in Acute Otitis Externa
PCRX Pacira Pharmaceuticals, Inc. 2016-11-01 Phase 3 NCT02713230 Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
PCRX Pacira Pharmaceuticals, Inc. 2016-11-01 Phase 3 NCT02713178 Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty
PTCT PTC Therapeutics, Inc. 2016-11-01 Phase 3 NCT02139306 Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
REPH Recro Pharma, Inc. 2016-11-01 Phase 3 NCT02678286 Evaluation of N1539 Following Abdominoplasty Surgery
RPTP Raptor Pharmaceutical Corp. 2016-11-01 Phase 3 NCT01744782 Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
TARO Taro Pharmaceutical Industries Ltd. 2016-11-01 Phase 3 NCT02933866 Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis